BRVE

Braveheart Bio, Inc. - Common Stock (BRVE)

About Braveheart Bio, Inc. - Common Stock (BRVE)

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Details

Daily high

$21.98

Daily low

$20.77

Price at open

$21.44

52 Week High

$32.00

52 Week Low

$18.00

Market cap

1.9B

Dividend yield

Volume

462,790

Avg. volume

628,023

P/E ratio

Braveheart Bio, Inc. - Common Stock News